Pharma News

Revenue for Linzagolix choline is expected to have a CAGR of -5.32% through 2038

Linzagolix choline is a Small Molecule owned by Kissei Pharmaceutical, and is involved in 18 clinical trials, of which 13 were completed, and 5 are ongoing.

Linzagolix choline acts as gonadotrophin-releasing hormone (GnRH) antagonist. GnRH antagonists suppress the production of the hormones LH and FSH. While GnRH agonists lead to an initial surge of the hormones FSH and LH, GnRH antagonists do not create this surge. The inhibition of GnRH receptors in the pituitary gland reduces circulating sex hormone levels.

The revenue for Linzagolix choline is expected to reach a total of $242m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Linzagolix choline NPV Report.

Linzagolix choline is originated and owned by Kissei Pharmaceutical.

Linzagolix choline Overview

Linzagolix (Yselty) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist. It is formulated as film coated tablets for oral route of administration. Yselty is indicated for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Linzagolix choline is under development for the treatment of endometriosis associated pain and uterine fibroids. It is a new chemical entity (NCE). The drug candidate is administered orally as a film coated tablet. KLH-2109 targets gonadotrophin-releasing hormone (GnRH).

Kissei Pharmaceutical Overview

Kissei Pharmaceutical (Kissei) discovers, develops, manufactures, and sells a range of innovative pharmaceutical products. The company’s pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drugs for obstetrics and gynecology, ophthalmic medicine and rare disease medicine. It also develops and sells health foods including protein-controlled food, energy supply food, calorie-controlled food, and elderly controlled food. Kissei conducts research to develop novel drugs and improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.

The company reported revenues of (Yen) JPY65,381 million for the fiscal year ended March 2022 (FY2022), a decrease of 5.3% over FY2021. The operating loss of the company was JPY1,842 million in FY2022, compared to an operating profit of JPY2,151 million in FY2021. In FY2022, the company recorded a net margin of 19.8%, compared to a net margin of 7.7% in FY2021.
The company reported revenues of JPY16,579 million for the second quarter ended September 2022, an increase of 1.8% over the previous quarter.

Quick View – Linzagolix choline

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
  • Central Nervous System
  • Non Malignant Disorders
  • Women’s Health
Key Companies
Highest Development Stage

Source link
#Revenue #Linzagolix #choline #expected #CAGR

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *